Skip to main content
. 2020 Nov 30;21:316. doi: 10.1186/s12931-020-01582-y

Fig. 1.

Fig. 1

Distribution and median of serum concentration of a SP-D, b SP-A and c KL-6 at baseline in patients with IPF in the phase 3 trial of pirfenidone in Japan. No numerical difference in the distribution was observed between the pirfenidone and placebo groups for each biomarker